Comment from National Ataxia Foundation
AnonymousSupportAdvocacy
Summary: The National Ataxia Foundation (NAF), a nonprofit patient advocacy group, supports the FDA's Rare Disease Innovation Hub (RDIH) and the RISE workshop series. They propose a future workshop topic focused on enhancing and clarifying how patient input, specifically through patient-focused drug development (PFDD) and advisory committees, is integrated into the drug review process to ensure transparency and consistency.
In response to FDA’s call for suggestions for future RISE workshop topics, the National Ataxia Foundation (NAF) is glad to provide our insight.